Additionally, there is an anticipation that demand-driven sales will normalize in early 2025, aligning with the discontinuation of compounded cantharidin. Although near-term revenue estimates have ...

TD Cowen lowered the firm’s price target on Verrica Pharmaceuticals (VRCA) to $10 from $15 and keeps a Buy rating on the shares. The firm ...